Rocio R. Macias

Salamanca, CL, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 101 publications

Tumour-autonomous IL-6 signalling creates a metabolic vulnerability in intrahepatic cholangiocarcinoma.

Tumour-autonomous IL-6 signalling creates a metabolic vulnerability in intrahepatic cholangiocarcinoma.

Journal: Gut

Published: April 16, 2026

Impact of CD44 alternative splicing on the response to anticancer drugs.

Impact of CD44 alternative splicing on the response to anticancer drugs.

Journal: Biochemical pharmacology

Published: March 05, 2026

Parenteral Berberine vs Cisplatin- Loaded Lipid Nanoparticles - Development, Characterisation, Comparative Safety Profiling and Cytotoxicity in Cholangiocarcinoma Cell Models.

Parenteral Berberine vs Cisplatin- Loaded Lipid Nanoparticles - Development, Characterisation, Comparative Safety Profiling and Cytotoxicity in Cholangiocarcinoma Cell Models.

Journal: Nanotechnology, science and applications

Published: January 14, 2026

Cholangiocarcinoma 2026: status quo, unmet needs and priorities.

Cholangiocarcinoma 2026: status quo, unmet needs and priorities.

Journal: Nature reviews. Gastroenterology & hepatology

Published: October 31, 2025

Impact of poly(rC)-binding protein 2 (PCBP2) on the malignant phenotype of cholangiocarcinoma.

Impact of poly(rC)-binding protein 2 (PCBP2) on the malignant phenotype of cholangiocarcinoma.

Journal: Biochemical pharmacology

Published: October 06, 2025

Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses.

Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses.

Journal: Hepatology (Baltimore, Md.)

Published: July 25, 2025

A three-gene resistome signature as a prognostic tool in hepatocellular carcinoma.

A three-gene resistome signature as a prognostic tool in hepatocellular carcinoma.

Journal: Annals of hepatology

Published: July 17, 2025

Pharmacological strategies to enhance the response of hepatoblastoma to chemotherapy through MDR1 inhibition.

Pharmacological strategies to enhance the response of hepatoblastoma to chemotherapy through MDR1 inhibition.

Journal: Acta pharmacologica Sinica

Published: July 10, 2025

Epidemiology, clinical, molecular features, and prognosis of early-onset biliary tract cancer: A systematic review and meta-analysis.

Epidemiology, clinical, molecular features, and prognosis of early-onset biliary tract cancer: A systematic review and meta-analysis.

Journal: JHEP reports : innovation in hepatology

Published: July 01, 2025

Drug-Resistant Cholangiocarcinoma Cell Lines for Therapeutic Evaluation of Novel Drugs.

Drug-Resistant Cholangiocarcinoma Cell Lines for Therapeutic Evaluation of Novel Drugs.

Journal: Molecules (Basel, Switzerland)

Published: June 10, 2025

Correction to "New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe" [The Lancet Regional Health - Europe, volume 50, March 2025, 101170].

Correction to "New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe" [The Lancet Regional Health - Europe, volume 50, March 2025, 101170].

Journal: The Lancet regional health. Europe

Published: May 19, 2025

Modulating Wnt/β-catenin pathway activity to enhance chemosensitivity in cholangiocarcinoma.

Modulating Wnt/β-catenin pathway activity to enhance chemosensitivity in cholangiocarcinoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 01, 2025

Showing 1-12 of 101

Last Updated: 09/26/2026